Table 2.
Clinical outcomes of critically ill patients with COVID-19 after PS matching
| Outcomes | Number of outcomes/Total number of patients | Odds Ratio (OR) (95%CI) | P-value $ | ||
|---|---|---|---|---|---|
|
DEX (n = 24) |
mPRED (n = 24) |
P-value | |||
| 30-day mortality, n (%) | 3 ( 14.3) | 6 ( 31.6) | 0.19** | 2.36 (0.51,10.86) | 0.27 |
| In-hospital mortality, n (%) | 4 ( 18.2) | 7 ( 35.0) | 0.22^^ | 2.31 (0.56,9.59) | 0.25 |
| beta coefficient (Estimates) (95%CI) | P-value $* | ||||
| Ventilator free days, Median (Q1, Q3) | 20.0 (4.00, 25.00) | 15.0 (0.00, 23.00) | 0.38^ | -0.20 (-0.99,0.60) | 0.63 |
| ICU Length of Stay (Days), Median (Q1,Q3) | 13.0 (6.00, 21.00) | 15.5 (9.00, 23.00) | 0.53^ | 0.34 (-0.10,0.77) | 0.13 |
| Hospital Length of Stay (Days), Median (Q1,Q3) | 21.5 (11.50, 29.00) | 19.5 (15.50, 29.50) | 0.81^ | 0.06 (-0.35,0.47) | 0.76 |
DEX Dexamethasone, mPRED Methylprednisolone
^Wilcoxon rank sum test is used to calculate the P-value
^^Chi-square test is used to calculate the P-value
$Logistic regression analysis used to calculate OR and p-value
$*Generalized linear model is used to calculate estimates and p-value